A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

NCT02655237 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

281

Enrollment

INDUSTRY

Sponsor class

Conditions

Uterine Fibroids

Interventions

DRUG: Relugolix
DRUG: Relugolix Placebo
DRUG: Leuprorelin
DRUG: Leuprorelin Placebo

Sponsor

Takeda